Tamsulosin can improve lower urinary tract symptoms in patients under active surveillance due to low risk prostate cancer: prospective controlled study

dc.authoridOrhan Tanrıverdi / 0000-0002-8105-6254
dc.authorscopusidOrhan Tanrıverdi / 6507392735
dc.authorwosidOrhan Tanrıverdi / F-2357-2013
dc.contributor.authorDalkılıç, Ayhan
dc.contributor.authorBayar, Göksel
dc.contributor.authorKılınç, Muhammet Fatih
dc.contributor.authorYavuz, Abdulmecit
dc.contributor.authorTanrıverdi, Orhan
dc.contributor.authorHorasanlı, Kaya
dc.date.accessioned2020-08-30T20:06:37Z
dc.date.available2020-08-30T20:06:37Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractObjective: We aimed to evaluate the efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in patients under active surveillance (AS) for low-risk prostate cancer (Pca). Materials and Methods: Patients who underwent prostate biopsy between 2010 and 2014 were evaluated prospectively. Inclusion criteria for AS were PSA level below 10 ng/mL, a tumor in a maximum of two cores, a tumor core percentage below 50%, a clinical stage <= T2a and a Gleason score <= 6. Patients under AS with LUTS were included in the study group and patients with benign pathology results with LUTS were included in the control group. International prostate symptom score (IPSS) and uroflowmetry test were used to evaluate LUTS. The maximum flow rate (Q(max)) was recorded. All patients received tamsulosin 0.4 mg once daily in a modified-release formulation (Flomax MR (R), Astellas, Japan). Transurethral resection prostatectomy (TUR-P) was performed when surgical treatment was necessary for obstruction despite tamsulosin treatment. Results: The study included a total of 91 patients, 41 patients in the AS group and 50 patients in the control group. Patients were assessed after six months. There was a 30% reduction in IPSS in the AS group and 24.5% in the control group (p=0.591). Q(max) increased by 20.4% in the AS group and by 20% in the control group (p=0.985). The need for TUR-P was similar between the two groups (14.6% vs 20%, p=0.503) during three-year follow-up. Conclusion: Tamsulosin can be used safely and with high efficacy for LUTS in patients under AS for low-risk Pca. The improvement in IPSS and Q(max), and the need for surgical treatment were similar to the control group.en_US
dc.identifier.citationDalkilic, A., Bayar, G., Kilinc, M. F., Yavuz, A., Tanriverdi, O., & Horasanli, K. (2019). Tamsulosin Can Improve Lower Urinary Tract Symptoms in Patients Under Active Surveillance Due to Low Risk Prostate Cancer: Prospective Controlled Study. UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 18(3), 107–112. https://doi.org/10.4274/uob.galenos.2018.1189en_US
dc.identifier.doi10.4274/uob.galenos.2018.1189en_US
dc.identifier.endpage112en_US
dc.identifier.issn2147-2270en_US
dc.identifier.issue3en_US
dc.identifier.startpage107en_US
dc.identifier.trdizinid379210en_US
dc.identifier.urihttps://doi.org/10.4274/uob.galenos.2018.1189
dc.identifier.urihttps://hdl.handle.net/20.500.12713/572
dc.identifier.volume18en_US
dc.identifier.wosWOS:000484342000004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorTanrıverdi, Orhanen_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofUroonkoloji Bulteni-Bulletin of Urooncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProstate Canceren_US
dc.subjectActive Surveillanceen_US
dc.subjectLower Urinary Tract Symptomsen_US
dc.subjectTamsulosinen_US
dc.titleTamsulosin can improve lower urinary tract symptoms in patients under active surveillance due to low risk prostate cancer: prospective controlled studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
15a.pdf
Boyut:
568.87 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text